Posts

Posted on

CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion CorporationShareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion CorporationShareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation (“Celsion” or “the Company”) (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/clsn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had significantly overstated the efficacy of ThermoDox; (2) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/clsn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Celsion you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

DEADLINE ALERT for ICPT, HPQ, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Class Period:   September 28, 2019 – October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE: HPQ)
Class Period: November 6, 2015 – June 21, 2016
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (2) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (3) that HP’s channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP’s inventory management metrics; and (4) that, as a result of the foregoing, defendants’ statements about the Company’s business condition and prospects were materially false and misleading when made.

Neovasc
Inc. (NASDAQ: NVCN)
Class Period: November 1, 2019 – October 27, 2020
Lead Plaintiff Deadline: January 5, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com



Posted on

ACB STOCK DEADLINE: Zhang Investor Law Reminds Investors With Losses of Deadline in Securities Class Action Lawsuit Against Aurora Cannabis Inc. – ACB

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1, 2020 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; the Company’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756



Posted on

ALYI Publishes $100 Million ICO Update From Finance Partner RevoltTOKEN

PR Newswire

DALLAS, Nov. 13, 2020 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI) today announced an update released from their financing partner, RevoltTOKEN.  The update from RevoltTOKEN CEO, Henryk Dabrowski, is included below:

RevoltTOKEN ICO Update

The response to the RevoltTOKEN ICO has been tremendous. We are here at RevoltTOKEN are humbled by the number of people contacting us ready to purchase Tokens. We are also encouraged by the response and in reaction to the response, confident that RevoltTOKEN will meet or exceed its $100 million funding objectives.

We are making steady progress on the necessary preparations for the ICO.  We are also trying to meet the eager market response by moving as quickly through the necessary preparations as possible.

We have previously announced that RevoltTOKEN is domiciling in Bermuda.  Cryptocurrency is a relatively new financing tool.  We have selected a sound technology platform, Ethereum, and we equally think it is important to prudently select a legal domain.

Bermuda is a globally respected business venue with a well-established and efficiently operating legal environment governing business transactions.  Bermuda has elected to take a leadership role in facilitating a cryptocurrency business environment with a standard of integrity that supports investor confidence.

As eager as we are to quickly launch the ICO, are eagerness is balanced by our prudence in carefully insuring a sound regulatory approach into an environment with only a short history of rules and regulations.

We are confident our internal investment resources can satisfy ALYI’s intermediate requirements pending the ICO. If necessary, we are willing to increase our existing interim investment commitments.

In Bermuda’s defense, since we have engaged to domicile and register as a cryptocurrency, Bermuda, like everyone, has had to deal with the restrictions of operating in a COVID environment in addition to dealing with a hurricane coming ashore followed by another near miss.  So, in addition to carefully managing a new financing tool, Bermuda is doing so in the face of some rather notable distractions.

In an effort to exercise the greatest prudence within the new cryptocurrency regulatory environment, RevoltTOKEN is currently exploring and intends to engage more than one registration venue. In addition to registering as a cryptocurrency in Bermuda, RevoltTOKEN intends to register in additional regulatory domains. 

The public trading of stocks has 400 years of history to draw on for regulatory standards.  Cryptocurrencies barely have a 10-year history since inception.  We anticipate a set of universal regulatory standards for cryptocurrencies someday similar to the universal standard for stocks.  At the moment, there is not much of a body of any rules and standards and different legal domains are developing different standards. Also, keep in mind, a larger number of cryptocurrencies trade today without being registered or licensed in any domain.

At RevoltTOKEN we think it is worthwhile to register in multiple domains in an effort to bridge the lack of a universal standard.

We look forward to the ultimate launch of the RevoltTOKEN ICO and working diligently to get there at the right time with the right amount of structure. We will continue to keep you posted on our progress.

For more information and to stay up to date on RevoltTOKEN’s latest developments, please visit www.revolttoken.com.

For more information and to stay up to date on ALYI’s latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc. Contact:
Randell Torno
[email protected]
+1-800-713-0297

Cision View original content:http://www.prnewswire.com/news-releases/alyi-publishes-100-million-ico-update-from-finance-partner-revolttoken-301172847.html

SOURCE Alternet Systems, Inc.

Posted on

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

ATLANTA–(BUSINESS WIRE)–
SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $291,000 (a loss of $0.04 per fully diluted share) for its first fiscal quarter ended September 30, 2020 compared to a loss of $143,000, (a loss of $0.02 per fully diluted share) for the quarter ended September 30, 2019. Net loss for the quarter ended September 30, 2020 was $340,000 (a loss of $0.05 per fully diluted share) compared to a net loss of $261,000 ($0.04 per fully diluted share) for the quarter ended September 30, 2019.

Consolidated net revenues from continuing operations for the quarters ended September 30, 2020 and 2019 were $10,422,000 and $11,652,000, respectively, a decrease of 10.6% in the current fiscal year’s first quarter compared to the comparable quarter of the prior fiscal year. Net revenues decreased in the current fiscal quarter primarily due to decreased hospital and nursing home net revenues and decreased Pharmacy segment revenues as a result of decreased sales in all product categories primarily due to the COVID-19 pandemic.

SunLink reported an operating loss for the quarter ended September 30, 2020 of $323,000 compared to an operating loss for the quarter ended September 30, 2019 of $220,000.

Loss from discontinued operations was $49,000 (or a loss of $0.01 per fully diluted share) for the quarter ended September 30, 2020 compared to a loss from discontinued operations of $118,000 ($0.02 per fully diluted share) for the quarter ended September 30, 2019.

COVID-19 Pandemic

A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance are very recent, rapidly changing and at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine.

In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 outbreak. There appears to be minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well in part due to the abrupt retirement of one physician and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.

Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at substantially reduced capacity. Until these referral sources are at full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the spreading of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID–19 pandemic and public and governmental responses to it negatively affected our last three fiscal quarters results.

During the fourth quarter of fiscal 2020, our Healthcare and Pharmacy segments received approximately $4,586,000 and in the first quarter of fiscal 2021 we received $106,000 in general and targeted Provider Relief Fund (“PRF”) distributions. During the fourth quarter of fiscal 2020, we also received $3,234,000 in Paycheck Protection Program (“PPP”) loans, administered by the Small Business Administration (“SBA”). Both the PRF and PPP funds are provided for under the Coronavirus Aid Relief and Economic Security (“CARES”) Act, and we have received a total of $7,926,000 of such funding.

The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for healthcare-related expenses or “Lost Revenues” (as defined by HHS) attributable to COVID-19. Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. HHS has released “CARES Act Provider Relief Fund Frequently Asked Questions” (“FAQ”) numerous times since April 3, 2020 through October 28, 2020 to clarify PRF requirements and has provided expansive examples of the reporting requirements in efforts to demonstrate what amounts of the PRF received may be considered to have been earned and may be retained. The Company continues to review and analyze the FAQ which it believes still leaves substantial uncertainty as to the proper use and reporting of PRF funds. We are reporting $31 of PRF in other income in our consolidated statement of operations for our fiscal quarter ended September 30, 2020 for COVID-19 related expenses. The unrecognized amount of the PRF are recorded under the caption “Unearned CARES Act Funds” in our consolidated balance sheets. We will continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the distributions received may be impacted. We currently believe we may not be able to utilize a portion of the PRF funds received under the currently existing interpretations by HHS and have to return the unutilized funds in the future.

Forgiveness of PPP loans may be available if the loans are used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds, subject to Federally-established terms and conditions. During July 2020, the allowable period for the use of PPP loan proceeds was amended to allow for a 24-week utilization period. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable period. The forgiveness applications are to be reviewed by both the lender and the SBA and a loan forgiveness amount, if any, will be determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company has not yet applied for forgiveness of any of its PPP loans and recorded no income relating to the PPP loans through September 30, 2020.

Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided, including the requirements applicable to PRF receipts and PPP loans.

SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate healthcare properties and businesses in the Southeast. Each of the Company’s businesses is operated locally with a strategy of linking patients’ needs with healthcare professionals. For additional information on SunLink Health Systems, Inc., please visit the Company’s website.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the company’s business strategy. These forward-looking statements are subject to certain risks, uncertainties and other factors, which could cause actual results, performance and achievements to differ materially from those anticipated. Certain of those risks, uncertainties and other factors are disclosed in more detail in the company’s Annual Report on Form 10-K for the year ended June 30, 2020 and other filings with the Securities and Exchange Commission which can be located at www.sec.gov.

 
SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES
FISCAL 2021 FIRST QUARTER RESULTS
Amounts in 000’s, except per share and volume amounts
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)

Three Months Ended September 30,

 

2020

 

2019

 

 

 

% of Net

 

 

 

% of Net

 

Amount

 

Revenues

 

Amount

 

Revenues
Net Revenues

$

10,422

 

 

100.0

%

$

11,652

 

100.0

%

Costs and Expenses:
Cost of goods sold

 

4,070

 

 

39.1

%

 

4,344

 

37.3

%

Salaries, wages and benefits

 

4,385

 

 

42.1

%

 

4,909

 

42.1

%

Supplies

 

224

 

 

2.1

%

 

319

 

2.7

%

Purchased services

 

647

 

 

6.2

%

 

703

 

6.0

%

Other operating expenses

 

949

 

 

9.1

%

 

1,103

 

9.5

%

Rents and leases

 

170

 

 

1.6

%

 

159

 

1.4

%

Depreciation and amortization

 

300

 

 

2.9

%

 

335

 

2.9

%

Operating Loss

 

(323

)

 

-3.1

%

 

(220

)

-1.9

%

 
Interest Expense – net

 

(7

)

 

-0.1

%

 

(30

)

-0.3

%

Federal stimulus – Pandemic relief funds

 

31

 

 

0.3

%

 

0

 

0.0

%

Gains on sale of assets

 

8

 

 

0.1

%

 

107

 

0.9

%

 
Loss from Continuing Operations before
Income Taxes

 

(291

)

 

-2.8

%

 

(143

)

-1.2

%

Income Tax expense (benefit)

 

0

 

 

0.0

%

 

0

 

0.0

%

Loss from Continuing Operations

 

(291

)

 

-2.8

%

 

(143

)

-1.2

%

Earnings (Loss) from Discontinued Operations, net of tax

 

(49

)

 

-0.5

%

 

(118

)

-1.0

%

Net Loss

$

(340

)

 

-3.3

%

$

(261

)

-2.2

%

Loss Per Share from Continuing Operations:
Basic

$

(0.04

)

$

(0.02

)

Diluted

$

(0.04

)

$

(0.02

)

Earnings (Loss) Per Share from Discontinued Operations:
Basic

$

(0.01

)

$

(0.02

)

Diluted

$

(0.01

)

$

(0.02

)

Net Loss Per Share:
Basic

$

(0.05

)

$

(0.04

)

Diluted

$

(0.05

)

$

(0.04

)

Weighted Average Common Shares Outstanding:
Basic

 

6,899

 

 

6,987

 

Diluted

 

6,899

 

 

6,987

 

 
HEALTHCARE FACILITIES VOLUME STATISTICS
 
Hospital and Nursing Home Admissions

 

66

 

 

122

 

Hospital and Nursing Home Patient Days

 

5,195

 

 

6,961

 

 
SUMMARY BALANCE SHEETS

September 30,

 

June 30,

 

2020

 

 

 

2020

 

ASSETS
Cash and Cash Equivalents

$

11,403

 

$

11,184

 

Accounts Receivable – net

 

4,195

 

 

4,315

 

Other Current Assets

 

4,420

 

 

4,424

 

Property Plant and Equipment, net

 

5,622

 

 

5,324

 

Long-term Assets

 

2,605

 

 

2,724

 

$

28,245

 

$

27,971

 

LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts Payable

$

1,614

 

$

872

 

Unearned CARES Act Funds

 

4,607

 

 

4,532

 

Other Current Liabilities

 

5,867

 

 

6,012

 

Long-term Debt and Other Noncurrent Liabilities

 

2,754

 

 

2,812

 

Shareholders’ Equity

 

13,403

 

 

13,743

 

$

28,245

 

$

27,971

 

 

Robert M. Thornton, Jr.

Chief Executive Officer

(770) 933-7004

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Hospitals Health Pharmaceutical Nursing Medical Supplies

MEDIA:

Logo
Logo
Posted on

PCS Edventures! Reports Unaudited Results for the Second Quarter of Fiscal Year 2021

BOISE, Idaho, Nov. 13, 2020 (GLOBE NEWSWIRE) — PCS Edventures!, Inc., (PCSV) a leading provider of K-12 Science, Technology, Engineering and Mathematics (STEM) education programs and drone products, today announced unaudited results of operations for its second quarter of Fiscal Year 2021 which ended on September 30, 2020.

Revenue was $0.39 million, which was down 54% from the revenue generated in the same period last year. Net income was ($0.21 million) compared to $0.58 million for the same period last year.

Michael Bledsoe, President, commented, “While schools are starting to cautiously go back to in-person learning, the classroom environment has changed. In more instances than not, school supplies and enrichment materials are no longer shared, sometimes by state mandate, with the intention of reducing the risk of COVID-19 transmission. This has presented a challenge for us, as many of our STEM products and curriculum include group activities designed to develop critical communication skills required in team environments. We continue to work with educators from all over the country to understand their needs and how we can best satisfy them.”

Mr. Bledsoe continued, “In response to our new environment, we have developed a program called BrickLABSTEAMventures to serve remote and social-distancing environments. Students use their own individualized set of bricks to engage in hands-on learning guided by STEAMventures activity books. The bricks are an initial purchase that can be reused with each new issue. We have also individualized some of our enrichment programs and are working with educators to determine the best way to teach the educational content of the program while staying in compliance with school safety guidelines.   We recognize the potential to market individualized kits and programs to retail consumers, especially given the increase in the home-schooling population, and we are working to address these new markets and opportunities. We are encouraged by early results of all of these efforts.”

For more information about PCS Edventures!, Inc., visit our website.

Company financial information and reports can be found at https://www.otcmarkets.com/.

About PCS
Edventures
!, Inc.

PCS Edventures!, Inc. (OTCPK: PCSV) is a Boise, Idaho company that designs and delivers technology-rich products and services for the K-12 market that develop 21st-century skills. PCS programs emphasize experiential learning in Science, Technology, Engineering, and Math (STEM). https://www.edventures.com/.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934; actual results could differ materially from such statements.

Contact

Investor Contact: Michael Bledsoe 1.800.429.3110, [email protected]
Investor Relations Web Site: pcsv.global



Posted on

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Biogen Inc. – BIIB

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Biogen Inc. – BIIB

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Biogen investors under the federal securities laws.

To join the Biogen class action, go to http://www.rosenlegal.com/cases-register-1981.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1981.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]
www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Posted on

BUSH’S® Beans Joins Chili Championship to Myrtle Beach

MYRTLE BEACH, S.C., Nov. 13, 2020 (GLOBE NEWSWIRE) — To bean, or not to bean. That is no longer a question at the World Championship Chili Cook-Off (WCCC), which will be held April 9-11, 2021, for the first time in Myrtle Beach, South Carolina.

The International Chili Society (ICS), the sanctioning body for the WCCC, announced today that it will be featuring BUSH’S® Beans as the presenting sponsor of the iconic cookoff.

“BUSH’S® Beans is a wonderful company with a great history, just like the World Championship Chili Cook-off,” commented Mike McCloud, the CEO of ICS. “For more than 50 years, our championship has delighted chili heads around the world with our Traditional Red and Verde categories of chili. And this year, our Homestyle division will be just as impressive as we welcome BUSH’S® to the table and invite chili cooks of all ages, including children, to Myrtle Beach for an incredible chili beach bash.”

For more than 100 years, chili fans seeking unparalleled flavor and quality have reached for BUSH’S. The brand’s Chili Beans, which are known for a special blend of chilies, spices, garlic and onions, will be on hand this year to help contestants make their best chili even better.

“BUSH’S is thrilled to sponsor the 2021 World Championship Chili Cookoffs,” said Brittanie Weaver, Bush’s Director of Marketing. “Our slow-simmered and perfectly seasoned Chili Beans have played a long standing role in different types of chili-inspired dishes, so we are excited to help show uninitiated chili-heads why BUSH’S Chili Beans are the Chili Beans of the pros.”

Almost $100,000 will be up for grabs at the 54th WCCC, which was started by legendary automotive enthusiast Carroll Shelby and friends. The 2021 categories include Traditional Red, Homestyle, Chili Verde, Veggie, and the much-anticipated return of Salsa. A “Last Chance” category will also be available to competitors who did not get the chance to qualify due to cook-off cancellations and an unprecedented year. Additionally, WCCC will host a “Corporate Cup Challenge” for local businesses in the Myrtle Beach Area that want to try their turn at Chili competition. To learn more information about the event, simply follow the World Championship Chili Cook Off on Facebook, Twitter and Instagram.  

About the International Chili Society 

Since 1967, the International Chili Society (ICS) has been bringing people together over one of America’s greatest culinary creations. ICS sanctions more than 100 events a year nationwide with one mission –  to continuously improve chili while raising money for charities and nonprofits. More than $100 million has been raised for charities by the chili arena since ICS was started. To celebrate each year’s pro-chili season, ICS holds a World Chili Championship Cookoff (WCCC) and crowns World Champions. To see previous winners, click here.

About BUSH’S® Beans

Family-owned since 1908, BUSH’S® is all about friends & family, and a certain Secret Family Recipe. When you enjoy BUSH’S Beans (doesn’t matter if they’re Baked Beans, chili beans, black beans, pinto beans…well, you get the picture), you can trust that they’re the very best. Because BUSH’S wouldn’t serve your family anything less. Since their start more than 110 years ago in Chestnut Hill, Tennessee, BUSH’S has always maintained that quality is the best policy. They pursue excellence and exceptional taste in their beans, sauces and everything we do. That’s why, from mouthwatering Baked Beans & Chili Beans to satisfying bean recipes, you’re cooking up the best with BUSH’S BEST®. For more information, visit www.bushbeans.com. 

Attachment 



Alli Sparks
International Chili Society
[email protected]

Posted on

Should you invest in Applied Materials, Xpeng Inc, Ross Stores, Apple, or American Airlines?

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for AMAT, XPEV, ROST, AAPL, and AAL.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/should-you-invest-in-applied-materials-xpeng-inc-ross-stores-apple-or-american-airlines-301172826.html

SOURCE InvestorsObserver

Posted on

Thinking about buying stock in Electrameccanica Vehicles, Moneygram International, GrowGeneration, Nokia, or Fisker?

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for SOLO, MGI, GRWG, NOK, and FSR.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-electrameccanica-vehicles-moneygram-international-growgeneration-nokia-or-fisker-301172829.html

SOURCE InvestorsObserver